Larimar Therapeutics Selected By FDA To Participate In Support For Clinical Trials Advancing Rare Disease Therapeutics Pilot Program For Nomlabofusp In Friedreich's Ataxia
Portfolio Pulse from Benzinga Newsdesk
Larimar Therapeutics has been selected by the FDA to participate in the START pilot program, which aims to accelerate the development of novel therapies for rare diseases. Their drug, Nomlabofusp, is being developed for Friedreich's Ataxia and has shown potential for clinical benefit. The program will enhance communication with the FDA to improve development efficiency, with a BLA submission targeted for the second half of 2025.
May 30, 2024 | 8:35 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Larimar Therapeutics has been selected by the FDA for the START pilot program to accelerate the development of Nomlabofusp for Friedreich's Ataxia. This selection highlights the potential clinical benefit of Nomlabofusp and aims to improve development efficiency through enhanced communication with the FDA. A BLA submission is targeted for the second half of 2025.
The FDA's selection of Larimar Therapeutics for the START pilot program is a significant endorsement of Nomlabofusp's potential. This could lead to accelerated development and regulatory approval, positively impacting LRMR's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100